Meeting
2022 ASCO Annual Meeting
Real-world use, tolerability, and dose modifications of PARP inhibitors in ovarian cancer.
Authors
David M. O'Malley
The Ohio State University, Columbus, OH
David M. O'Malley , Rebecca Christian Arend , Naufil Alam , Ozan Ozgoren , Kimmie K. McLaurin , Grainne H. Long , Susana N. Banerjee
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 5552)
DOI
10.1200/JCO.2022.40.16_suppl.5552
Abstract #
5552
Poster Bd #
431
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Risk of secondary hematologic malignancies in patients with ovarian cancer treated with PARP inhibitors: A combined meta-analysis of seven phase III randomized controlled trials.
First Author: Thura Htut
Poster
2017 ASCO Annual Meeting
Evaluating the cost-effectiveness of current FDA-approved PARP inhibitors for the treatment of recurrent ovarian cancer.
First Author: Juliet Elizabeth Wolford
Poster
2021 ASCO Quality Care Symposium
Reasons for first-line maintenance therapy discontinuation among patients with newly diagnosed advanced ovarian cancer treated in real-world settings.
First Author: Jinan Liu
Poster
2020 ASCO Virtual Scientific Program
Population-adjusted indirect treatment comparison (PAITC) of maintenance PARP inhibitor (PARPi) with or without bevacizumab versus bevacizumab in women with newly diagnosed ovarian cancer (OC).
First Author: Robert Hettle